Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

Core Insights - Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, as part of a $23 billion investment in US infrastructure over the next five years [1][4][5] - The Carlsbad facility will enhance Novartis' capacity to meet future demand for RLT, which is a form of precision medicine designed to deliver targeted radiation to tumors [2][3][8] - Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio, and this facility is its third RLT manufacturing site in the US, reinforcing its leadership in the field [4][6] Company Commitment - Novartis plans to invest nearly $50 billion in its US operations over the next five years, reflecting a strong commitment to the US healthcare ecosystem [5][6] - The Carlsbad facility is purpose-built for manufacturing FDA-approved RLTs and has the capacity for future expansion [4][6] - The company is also expanding its manufacturing footprint with additional facilities planned in Florida and Texas, and is establishing a second global R&D hub in San Diego, California [7][9] Industry Impact - The opening of the Carlsbad facility is expected to strengthen California's position as a hub for life sciences innovation and create new job opportunities in engineering and manufacturing [5] - Novartis is actively investigating the application of RLTs across various cancer types, with one of the most advanced pipelines in the industry [9] - The company has a proven track record of delivering RLT at scale, maintaining an on-time delivery rate of over 99.9% to patients across the western US, Alaska, and Hawaii [6]